However, there are several studies demonstrating an upregulation of CB2 on activated microglial cells (macrophages of the CNS), rendering the receptor a promising target to exploit neuroinflammatory changes involved in neurodegenerative disorders such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), Parkinson's or Alzheimer's disease (Benito et al., 2008; Onaivi, 2009). The gene discussed is CNR2; the disease is amyotrophic lateral sclerosis.